Background: Current methods for obtaining fetal cells for prenatal diagnosis are invasive and carry a small (0.5-1.0%) but definite risk of miscarriage. An attractive alternative would be isolation of fetal cells from peripheral maternal blood using antibodies with high specificity and avidity. Methods: To generate antibodies, we purified nucleated red blood cells (NRBCs) from fetal livers and used them as the immunogen to generate monoclonal antibodies (mAbs) directed against surface antigens. Results: The four antibodies recognized at least two conformationally sensitive epitopes of the transferrin receptor. Isolation of NRBCs from 252 maternal blood samples using these antibodies in magnetic activated cell sorting after an initial density gradient centrifugation yielded 0 -419 NRBCs per 25 mL of maternal blood. One antibody, 2B7.4, not only isolated the highest number of NRBCs (>10 in 90% of the samples) but also isolated these NRBCs in 78 consecutive maternal samples. Conclusion: Antibody 2B7.4 shows promise for the isolation of NRBCs from maternal blood and should allow studies concerning the source of these cells, fetal vs maternal, and the factors controlling their prevalence.
For prenatal genetic testing (1, 2 ) , an attractive strategy is to isolate fetal cells from peripheral maternal blood and genetically test them for inherited disease. Fetal nucleated red blood cells (NRBCs) 6 are good candidates for the purpose of prenatal diagnosis for several reasons. They are mononuclear, abundant in first trimester fetal blood, and rare in adult peripheral blood (3, 4 ) . In addition, nucleated erythrocytes express several antigens, such as the transferrin receptor expressed on rapidly dividing cells, that might be useful targets for enriching samples of maternal blood. These cells also produce unique fetal hemoglobin chains such as , ⑀, and ␥ (5 ), providing useful markers of fetal cells. Finally, erythrocytes are unlikely to persist from one pregnancy to the next (6 ) . However, controversy exists regarding the origin of the NRBCs in maternal blood: some authors state that most nucleated erythrocytes in first trimester maternal blood are of maternal origin (7, 8 ) .
The rarity of fetal cells in maternal circulation necessitates several enrichment techniques. A single, double, or triple density gradient is commonly used before separation strategies such as fluorescence-activated cell sorting (FACS) (9 -12 ) , magnetic activated cell sorting (13) (14) (15) , immunomagnetic beads (16, 17 ) , antibody-conjugated columns (18 ) , and charge flow separation (19, 20 ) .
The most common strategy to enrich NRBCs uses a monoclonal antibody (mAb) that binds a cell surface antigen present on fetal NRBCs. The most widely used mAbs for fetal NRBC isolation are those directed against the transferrin receptor (CD71) (21, 22 ) , the throm-bospondin receptor (CD36) (23 ) , and glycophorin A, a red cell sialoglycoprotein (21, 24 ) .
To improve the purity and yield of fetal NRBCs isolated from maternal blood and to investigate the biology of materno-fetal transfer of cells, we produced and characterized murine mAbs to human fetal liver NRBCs and used some of these antibodies to isolate NRBCs from maternal blood.
Materials and Methods preparation of fetal NRBCs
Fetal liver tissue samples were obtained from medically approved terminations at 15-20 weeks of gestation. NRBCs were isolated essentially as described by Bhat et al. (25 ) except that Histopaque 1107 was used at the bottom of the double density gradient.
A negative procedure was used to remove leukocytes. Cells (2 ϫ 10 9 ) in 2 mL of phosphate-buffered saline containing 5 mmol/L EDTA, 1 g/L human serum albumin, and 0.5 g/L NaN 3 (PBS/HSA buffer) were incubated with 50 L of microbeads coated with antibodies to CD45, CD14, CD15, or CD16 (Myltenyi Biotec) for 30 min at 4°C. The cell-microbead mixture was washed and passed over a Myltenyi (Myltenyi Biotec) type CSϩ magnetic separation column (2 ϫ 10 8 bound cell capacity) according to the instructions of the manufacturer. The purity of the resulting NRBC preparation was assessed by visually examining cytospins (Shandon cytospin 3) stained with the nuclear stain giemsa and with 3,3Ј-dimethoxybenzidine, which stains hemoglobin.
development of hybridomas
Mice were immunized by intraperitoneal injections of 3 ϫ 10 6 to 6 ϫ 10 6 fetal NRBCs every 2 weeks for 6 weeks. All mice received an additional injection of NRBCs 72 h before fusion. Cell fusion was performed by the method of Waldman (26 ) with the P3 ϫ 63-Ag8.653 myeloma fusion partner by the Washington University Hybridoma Center (St. Louis, MO). The hybridomas were screened for binding to cell surface antigens on fetal NRBCs by FACS analysis. Fetal NRBCs (40 L) resuspended in PBS/HSA (1 ϫ 10 6 cells) were incubated in 96-well plates with 10 L of hybridoma supernatant for 30 min at 4°C with agitation. The positive and negative controls were antibodies to CD71 and CD45, respectively (Becton Dickinson). After two washes, the cells were incubated as above with 40 L of a 1:50 dilution of goat anti-mouse IgG Fab conjugated to fluorescein isothiocyanate (Sigma Diagnostics). The cells were washed again and resuspended in 500 L of PBS for analysis in a FACScan (Becton Dickinson).
Adsorption of positive hybridomas to adult red blood cells (RBCs), subtypes A and B, eliminated mAbs to mature RBC antigens. We incubated 1 ϫ 10 8 adult blood cells with 200 L of hybridoma supernatant for 30 min at 4°C with gentle agitation. After centrifugation, 150 L of supernatant was incubated with 1 ϫ 10 6 fetal NRBCs and screened as described above. The same supernatants without adsorption were analyzed concurrently. Only the hybridomas with unchanged positive fluorescence were considered specific for fetal NRBCs. Anti-fetal NRBC mAbs were produced in ascites fluid and purified by protein A-agarose chromatography (Genex).
immunohistochemistry
The human T-cell lymphoblastoid cell line CEM, which expresses 5-to 100-fold more CD71 than normal resting lymphocytes (27 ) Nuclei were removed by centrifugation at 300g for 10 min at 4°C, and the resulting supernatant was made 2 g/L sodium deoxycholate. Unsolubilized membranes were removed by centrifugation at 48 000g for 1 h at 4°C. Antigen was immunopurified from the supernatant as described by Springer (29 ) except that 0.1-mL columns of immunoabsorbant were used. The mean yield was 50 g protein per 1 ϫ 10 9 NRBCs, estimated by the Bradford (30 ) protein assay (Bio-Rad). Purified antigen was stored at Ϫ70°C until use.
Clinical Chemistry 45, No. 9, 1999 antigen identification Antigen was digested with a CNBr mixture consisting of 239 L of 880 mL/L formic acid (Aldrich), 46 L of 0.35 g/L affinity-purified antigen, and 15 L of 5 mol/L CNBr in acetonitrile (Aldrich) and reacted overnight. Samples were electrophoresed on 4 -20% sodium dodecyl sulfatepolyacrylamide electrophoresis (SDS-PAGE) minigels (31 ) with subsequent electrotransfer to PSQ-grade polyvinylidene difluoride membranes (Sigma), using a threebuffer semidry blotting system (32 )(ESA); the stained bands were Edman sequenced (31 ) . The unstained membrane was analyzed by Western blotting, using Amersham Life Sciences AuroProbe BL plus gold-labeled goat anti-mouse as the secondary mAb, and bands were detected using the silver enhancement kit.
enrichment of NRBCs from maternal blood
After informed consent was obtained under a protocol approved by San Agustín Hospital, 25-mL blood samples were collected from 252 pregnant women into Vacutainer Tubes containing EDTA anticoagulant. The majority of the women were average risk patients participating in routine prenatal screening recruited from clinical sites throughout the Principado de Asturias. In all cases, gestational age was confirmed by sonogram. Because amniocentesis was performed in only a few cases, we analyzed most of the samples without knowledge of fetal gender.
Mononuclear cells from peripheral maternal blood were isolated on a double histopaque gradient. The washed cells were resuspended in PBS/BSA/azide to a final concentration of 1 ϫ 10 6 cells per 100 L and incubated with 3 g of one of our mAbs for 20 min at 4°C. The cells were then incubated with magnetic microbeads conjugated to rat anti-mouse IgG antibody (20 L per 10 7 cells; Miltenyi Biotech) for 20 min at 4°C and separated on the Miltenyi miniMACS magnetic column type MS (1 ϫ 10 7 bound cell capacity) as described by the manufacturer. The NRBCs were enumerated on cytospins.
pcr Sorted cells were pelleted at 10 000g and snap frozen. For PCR, the cells were resuspended in 35 L of water and boiled for 10 min. The following primer sequences were used:
Xes14: 5Ј-GTC GCA CTC TCC TTG TTT TTG AC-3Ј Xes15: 5Ј-CCG ATT GTC CTA CAG CTT TGT C-3Ј SRY4: 5Ј-GGC TCT AGA GAA TCC CAG AAT GCG A-3Ј SRY5: 5Ј-GGC TTC AGT AAG CAT TTT CCA CTG G-3Ј Primers XES14 and XES15 flanked a single copy of Y-specific sequence consisting of 600 bp; primers SRY4 and SRY5 flanked a 80-bp sequence nested within the 600-bp sequence (33 ) .
PCR mixture containing 1.7 mmol/L MgCl 2 , 0.2 mmol/L each dNTP, 200 ng of each primer (Integrated DNA Technologies), and 1 U of Taq polymerase (Boehringer Mannheim) in 50 L of the PCR buffer provided by the manufacturer. The first of two amplifications was with primers Xes14 and Xes15; the reaction was denatured at 94°C for 10 min and then underwent 34 cycles of denaturation at 94°C for 1 min, annealing at 58°C for 45 s, and elongation at 72°C for 1, followed by a final 10 min at 72°C. The second amplification was performed with 10 L of the reaction product in fresh reagents and using the primers SRY4 and SRY5; a 2-min denaturation at 94°C was followed by 34 cycles of denaturation at 94°C for 20 s, annealing at 58°C for 45 s, and elongation at 72°C for 1 min, and then by a final 10 min at 72°C.
Results
NRBCs purified from fetal liver and used as immunogen are depicted in Fig. 1, which shows that the majority of the cells are erythroblasts and NRBCs. From the group of antibodies specific for NRBCs in FACS analysis, four of the most effective were selected for further characterization. Table 1 summarizes the staining data for these four mAbs plus commercial antibodies to CD71. The mAbs stained NRBCs, CEM cells, and some mature RBCs, but not WBCs. This demonstrated specificity of the mAbs for NRBCs and implicated CD71 as the antigen recognized because the CEM cells overexpress this protein (27 ) . Activated lymphocytes are also reported to express the transferrin receptor (27 ) , and the in vitro-activated WBCs did stain albeit weakly. The staining of some mature RBCs may simply indicate that these are reticulocytes, which still display some transferrin receptor (34 ). Staining was not observed with a-CD71 (Becton Dickinson), the mAb to CD71 frequently used for sorting NRBCs, even at concentrations up to 10 mg/L, whereas our mAbs stained effectively at concentrations of 0.1-4 mg/L. This same a-CD71 mAb does bind to NRBCs because it was used as a positive control in our FACS screen of the hybridomas. Competitive binding experiments (data not shown) indi- cated that two of our mAbs (4B2.1 and 2F6.3) react with a similar epitope, whereas the other two (2E11.3 and 2B7.4) recognize a different one. Thus, our mAbs recognize at least two epitopes. The data also indicate that the Becton Dickinson a-CD71 mAb either binds to a third epitope or that it binds with much lower avidity.
To confirm the identity of the antigen as transferrin receptor, we used our mAb immobilized on agarose as affinity columns to immunopurify antigen from fetal liver NRBCs. Two Coomassie-stained bands of approximately equal intensity were seen that migrate in the 85-110 kDa range under reducing conditions on 4 -20% SDS-PAGE (Fig. 2, lane 2) . A Western blot of a duplicate lane indicated that only the ϳ110-kDa band reacted with a commercial anti-human transferrin receptor mAb H68.4 (Zymed) specific to residues 3-28 of the cytoplasmic tail (Fig. 2, lane 3) . Immunoblots with our mAbs yielded only a very weakly stained ϳ110-kDa band even after reaction with gold-labeled secondary mAb and three 45-min rounds of silver enhancement (data not shown).
In a separate experiment, the immunopurified proteins were transferred to polyvinylidene difluoride membranes and then Edman sequenced. No sequence was found for the ϳ110-kDa species, but the ϳ85-kDa band gave an 11-residue N-terminal sequence identical to human transferrin. The inability to sequence the 110-kDa antigen suggested a blocked NH 2 terminus, thus requiring an internal amino acid sequence (35 ) for positive identification. Five major bands were discernible after CNBr digestion that corresponded to molecular masses of ϳ36, 29, 22.5, 17, and 14 kDa (not shown). Sequencing of 9 -12 residues of these fragments allowed identification of the parent protein as the transferrin receptor, which is known to exist as a transmembrane, glycosylated, disulfidelinked homodimer (36 ) . Under our experimental conditions, transferrin copurified with its receptor.
Data on the enrichment of NRBCs from maternal blood using our four mAbs are presented in Fig. 3 . Blood was obtained from 252 pregnant women at 15-18 weeks of gestation and was processed between 2 and 24 h after collection. The absolute number of NRBCs isolated from 25 mL of maternal blood ranged from 0 to 419 with three of the mAbs and from 3 to 336 with mAb 2B7.4. This mAb isolated 3-10 NRBCs in 10% of the samples, 11-50 NRBCs in 60% of samples, and 51-336 NRBCs in 30% of the maternal blood samples. We also found that the median and mean numbers of isolated NRBC were higher in samples processed between 2 and 6 h after maternal blood collection and that maternal WBC counts were higher in older samples (data not shown). In four samples in which the sex of the fetus was known, the enriched NRBC sample was split into three aliquots: one for microscopic examination and two for Y-chromosome PCR. shows the PCR results for these four samples of enriched NRBCs. The PCR results confirmed the sex of the fetus established by amniocentesis.
Discussion
Purification of fetal NRBCs for prenatal diagnosis presents a difficult challenge. The number of these cells in peripheral maternal blood has been reported to range from 1:10 4 to 1:0 8 WBCs (3, 19, 21, 37, 38 ) . Because in adult women there are 6 ϫ 10 6 to 9 ϫ 10 6 WBCs per milliliter of blood, this translates into a reported range of 1-1800 NRBCs per 20 mL of maternal blood. However, the reported ranges of recovered NRBCs are much lower than this range (39 -41 ) with the exception of Wachtel et al. (19 ) .
The inconsistent presence of NRBCs in all pregnancies (7, 37, 39, 42 ) and the low yield reported suggest several questions that remain to be answered before the clinical utility of isolating fetal NRBCs for prenatal genetic diagnosis can be established. These questions involve whether fetal cells are present in all pregnancies and the extent to which the number of fetal cells are dependent on fetal status, gestational time, or maternal complications. To address these questions, we decided to develop reagents that might give better yields of fetal cells.
Our strategy was to generate high avidity, specific mAbs against fetal NRBCs by immunizing mice with fetal NRBCs purified from fetal livers. Our screening protocol selected mAbs that had high affinity for NRBCs but not for mature RBCs. The prominent surface antigen was identified as transferrin receptor (CD71), and competitive binding studies showed that mAbs 2E11.3 and 2B7.4 bind a similar epitope, whereas 4B2.1 and 2F6.3 bind to a different epitope on the transferrin receptor.
The weak reactivity of mAbs 4B2.1 and 2E11.3 in Western blots suggests that the mAbs recognize conformationally dependent epitopes on the receptor that are destabilized under denaturing conditions (43 ) . Because 2E11.3 binds a different epitope than 4B2.1 and 2F6.3, both epitopes are conformationally sensitive.
The NRBC enrichment procedure, consisting of a double density gradient followed by magnetic activated cell sorting with four of our mAbs, was applied to 252 maternal blood samples. The mean number of NRBCs obtained varied with the mAb (Fig. 3) . More NRBCs were isolated when mAb 2B7.4 was used than the other three mAbs were used; 2E11.3 isolated the least. The mean number of NRBCs obtained using our enrichment procedure (0 -419 per 25 mL of blood) is similar to that (0 -220 per 30 mL of blood) reported by Oosterwijk et al. (44 ) . However, we isolated one or more NRBCs in 96% of the samples, whereas Oosterwijk et al. detected NRBCs in only 66% of their cases. Our NRBC/leukocyte (purity) ratio was improved compared with these results (44 ) and those reported elsewhere (20, 21, 39, 41 ) . An important factor in this ratio appeared to be the time between blood collection and gradient separation, which was also observed by Oosterwijk et al. (45 ) . The lowest WBC contamination was observed when the cells were processed within 6 h of collection. Because our samples came from throughout Asturias, many of them could not be processed that quickly; however, all were processed within 24 h. mAb 2B7.4 not only isolated the highest number of NRBCs (Ͼ10 cells in 90% of the samples), but it isolated NRBCs in all 78 consecutive maternal blood samples studied, a success rate not described in the literature previously. Thus, 2B7.4 isolates sufficient NRBCs for fluorescence in situ hybridization and/or PCR in 90% of the cases and in the remaining 10% should provide sufficient cells for PCR analysis. It should be emphasized The total number of samples tested with each mAb was 78 with 2B7.4, 68 with 2E11.3, 57 with 2F6.3, and 48 with 4B2.1. mAb 2B7.4 isolated three or more NRBCs in all samples. The NRBC/leukocyte ratios were as follows: 1:4 to Ͼ1:300 for 2B7.4; 1:22 to Ͼ1:300 for 2E11.3; 1:5 to Ͼ1:300 for 2F6.3; and 1:7 to Ͼ1:300 for 4B2.1. The yield of NRBCs using mAb 2B7.4 was significantly better than the other three antibodies (P Յ0.0002, Wilcoxon rank-sum test). that the high NRBC yields with our mAbs were obtained in blood samples from a healthy population of pregnant women, not from a high-risk population in which higher yields of NRBCs have been reported (38 ) .
To determine whether any of the NRBCs isolated from maternal blood were of fetal origin, PCR for the Y and X chromosomes was performed on some of the samples. In two cases in which a male pregnancy was known, the PCR correctly identified the Y chromosome, indicating a fetal source for the NRBCs (Fig. 4) . Subsequent PCR analysis detected the Y chromosome in 40% of 50 samples, and follow-up information will provide the gender at delivery (F.V. Alvarez, personal communication).
Further optimization of the enrichment procedure may be possible. For example, selective lysis of mature RBCs after the density gradient spin to remove reticulocytes, which may still express some transferrin receptor, may improve yields with mAbs 4B2.1 and 2F6.3. The simultaneous use of mAbs to different epitopes on the transferrin receptor may also increase yield. Work is in progress to identify the isolated NRBCs as fetal or maternal in origin, using fluorescence in situ hybridization for the Y chromosome and immunostaining for ␥ or ⑀ fetal hemoglobin.
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